Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)

Overview

This study aims to evaluate the role of PSMA-PET and circulating tumor DNA (ctDNA) in monitoring prostate cancer progression and response to radiotherapy (RT). Specifically, it investigates how often early progression is detected on PSMA-PET before PSA rise, examines PET responses of lesions treated with RT at 6 and 12 months and their correlation with PSA changes and later progression, examines ctDNA changes following ablative-intent RT to metastatic sites, and explores the relationship between PSMA-PET radiological findings and ctDNA dynamics.

Detailed description

Primary Objective:

\* Identify the frequency of early progressive disease on PSMA-PET prior to PSA progression.

Secondary Objectives:

* Describe the PET response to lesions given RT at 6 months (and 12 month if applicable), and its relationship to PSA changes, and to later progressive disease both on PET and with PSA progression for each cohort * Characterize the changes in ctDNA levels after ablative-intent RT to metastatic sites. * Describe the radiological changes from PSMA-PET and its relationship with ctDNA.

Interventions

• Drug ADT
  Androgen Deprivation Therapy
• Drug ARSI
  Androgen Receptor Signaling Inhibitor
• Other No ADT/ARSI -decline
  Recurrent prostate cancer with oligometastatic disease who decline ADT/ARSI and are treated with ablative intent RT alone and who have \<=5 extrapelvic lesions detected on a baseline PSMA-PET and have rising PSA.

Primary outcome measures

• Early PD on PSMA-PET prior to PSA-progression [Time frame: Up to 5 years]

Secondary outcome measures (2)

• Describe the PET response to lesions and its relationship to PSA changes [Time frame: Up to 5 years.]
• Characterize the changes in ctDNA levels [Time frame: Up to 5 years.]

Eligibility criteria

Inclusion criteria

• Documented informed consent of the participant or legally authorized representative.
• Age: ≥ 18 years
• KPS ≥ 70 or ECOG 0-1 (Appendix A)
• Biopsy-confirmed diagnosis of castration-sensitive prostate adenocarcinoma, as defined by rising PSA in setting of T>100
• Clinical diagnosis of de novo oligometastatic or oligoprogressive disease, as defined by one the following:

De novo oligometastatic: newly diagnosed prostate cancer AND ≤ five metastatic sites outside of the pelvis (Metastatic sites may not be brain or liver.) OR Hormone Sensitive Oligoprogressive: history of prior local therapy for prostate cancer AND ≤ five progressing metastatic sites outside of the pelvis (Metastatic sites may not be brain or liver.) AND Hormone sensitive defined as clinical progression in absence of castration (T>100)

• Measurable disease by PERCIST v1.0
• Eligible to receive ablative-intent radiation therapy (biologically effective dose \[BED\] >100, α/β ratio:2) directed to all sites of metastatic disease.
• Primary site of disease (Prostate +/- Seminal Vesicles) is controlled or will receive ablative intent treatment as a part of this treatment course.
• Baseline flotufolastat F18 PET imaging, if obtained as part of standard of care, is acceptable provided it was performed prior to the initiation of radiation therapy.
• Agreement by females and males of childbearing potential\* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 30 days after the last dose of protocol therapy. \* Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only).

Exclusion CriteriPrior and concomitant therapies

• Any patient planning to receive lifelong continuous or intermittent ADT
• For the current treatment course, patient must not have received more than 3 months of neoadjuvant ADT prior to consent.
• Any contraindication to receiving flotufolastat F 18.
• Diagnosis of polymetastatic (newly diagnosed prostate cancer and more than five metastatic sites outside of the pelvis or metastatic sites in brain or liver.)
• Diagnosis of polyprogressive disease (History of metastatic prostate cancer with more than five progressive metastatic sites outside of the pelvis or metastatic sites in brain or liver).
• Patients with a history or evidence of HIV infection (unless on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial).
• Patients with history or evidence of chronic hepatitis B virus (HBV) infection (unless HBV viral load is undetectable on suppressive therapy).
• Patients with a history or evidence of hepatitis C virus (HCV) infection (unless treated and cured. Patients with HCV infection who are currently on treatment are eligible if they have an undetectable HCV viral load).
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent.
• Any contraindications to undergo PSMA-PET.
• Clinically significant uncontrolled illness.
• Other active malignancy. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
• Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.
• Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Non-randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 1 center

• City of Hope Medical Center — Duarte

Identifiers

NCT: NCT07210086 · 25339 · P30CA033572 · NCI-2025-07236 · 25339

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗